Global Antipsychotic Drugs Market
Global Antipsychotic Drugs Market

Antipsychotic Drugs Comprehensive Study by Type (First Antipsychotic Drugs (Typical Antipsychotics), Second Antipsychotic Drugs (Newer Drugs), Third Antipsychotic Drugs), Application (Schizophrenia, Bipolar Disorder, Depression, Dementia, Others), Drug Class (Haldo, Navane, Invega, Latuda, Seroquel, Risperdal, Zyprexa, Geodon, Abilify) Players and Region - Global Market Outlook to 2026

Antipsychotic Drugs Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 211 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Antipsychotic Drugs Market Overview:
According to the World Health Organization (WHO), there are an estimated 300 million people who are affected by depression and 60 million people who are affected by bipolar disorders worldwide which result in the demand of antipsychotic drugs. One-fourth of people are affected by mental or neurological disorders at some point in their lives. Psychosis is a group of disorders with serious distortion of thought, behavior, recognition of reality and perception. The patient can experience delusions and hallucinations and may have misperception and wrong evaluation of the situation, facts or other people. Antipsychotic drugs are one of the top-selling and most widely prescribed drugs for managing psychotic conditions in the United States. The increasing prevalence of psychosis and diseases associated with it are driving the Global Antipsychotic Drugs.

Growth Drivers
  • Introduction of new Antipsychotic Compounds by researchers
  • The rising prevalence of mental health disorders such as Schizophrenia and Bipolar Disorder
  • With the increasing cases of Psychotic Disorder leading to increase the interest of the Government in R & D of such type of drugs.

Market Trends
  • Increasing cases of addiction Antipsychotic Drugs resulting in drug abuse and addiction
  • Schizophrenia patients are reported to be more prone to drug abuse and addiction.

Roadblocks
  • Poor Efficiency and Efficacy of Antipsychotic Drugs
  • The impending patent expirations of several blockbuster drugs and threat of cheap generics used in the market

Opportunities
  • High investment for R & D and increasing efforts by the market players to expand therapeutic application in this area are anticipated to provide opportunity to the market in the forecast period.

Challenges
  • Adverse effects of the drugs like Insomnia, dry mouth, drowsiness, blurred vision impacting patients health is posing a challenge for the market.


Competitive Landscape:
The market appears to be fragmented by the many players who are introducing generic versions of antipsychotic drugs and have begun investigating new therapeutic applications for these products hence the generic products are slowly replacing the established brands in antipsychotic market. Moreover, Pharmaceutical companies are still significantly investing in the development of novel antipsychotic drugs. Moreover, Rapid discoveries on antipsychotic drugs are being carried out by researchers such as According to National Institute of Health (NIH), In January 2018 research funded by them, Antipsychotic Risperidone could help in the creation of better treatments for schizophrenia, bipolar disorder, and other mental illnesses. They could understand that how atypical antipsychotic drugs bind to primary molecular target in the human brain.
Some of the key players profiled in the report are Eli Lilly & Co. (United States), Bristol-Myers Squibb (United States), AstraZeneca (United Kingdom), Pfizer Inc. (United States), GlaxoSmithKline plc. (United Kingdom), Johnson & Johnson (United States) and Allergan (Ireland). Additionally, following companies can also be profiled that are part of our coverage like Takeda Pharmaceutical Company Limited (Japan), H. Lundbeck A/S (Denmark), Otsuka Pharmaceuticals (Japan) and Proteus Digital Health (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Antipsychotic Drugs market by 2026. Considering Market by Drug Class, the sub-segment i.e. Haldo will boost the Antipsychotic Drugs market.

Latest Market Insights:
In October 2018, Proteus Digital Health has collaborated with Ostuka Pharmaceuticals on a pipeline of digital, oral solid-dosage drugs for various therapies, including cardiovascular and oncology drugs, based on its first NDA (New Drug application) ABILIFY MYCITE which received FDA approval in November 2017, The drug used ingestible sensors in an antipsychotic treatment.

In September 2018, Takeda Pharmaceutical Company Limited and H. Lundbeck A/S announced that U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for TRINTELLIX (Vortioxetine) in Japan for the treatment for Major Depressive Disorder (MDD). and A study conducted for this drug suggested that Pivotal phase III trial demonstrated positive results of Vortioxetine as compared to placebo for the treatment of MDD in Japanese adults.

What Can be Explored with the Antipsychotic Drugs Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Antipsychotic Drugs Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Antipsychotic Drugs
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Antipsychotic Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Antipsychotic Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Anti-psychotic Drugs Manufacturers, Anti-psychotic Drugs Suppliers, Private Research Laboratories, Research and Development (R&D) Companies, Market Research and Consulting Service Providers, Government Research Laboratories and Contract Manufacturing Organizations.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • First Antipsychotic Drugs (Typical Antipsychotics)
  • Second Antipsychotic Drugs (Newer Drugs)
  • Third Antipsychotic Drugs
By Application
  • Schizophrenia
  • Bipolar Disorder
  • Depression
  • Dementia
  • Others
By Drug Class
  • Haldo
  • Navane
  • Invega
  • Latuda
  • Seroquel
  • Risperdal
  • Zyprexa
  • Geodon
  • Abilify

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Introduction of new Antipsychotic Compounds by researchers
      • 3.2.2. The rising prevalence of mental health disorders such as Schizophrenia and Bipolar Disorder
      • 3.2.3. With the increasing cases of Psychotic Disorder leading to increase the interest of the Government in R & D of such type of drugs.
    • 3.3. Market Challenges
      • 3.3.1. Adverse effects of the drugs like Insomnia, dry mouth, drowsiness, blurred vision impacting patients health is posing a challenge for the market.
    • 3.4. Market Trends
      • 3.4.1. Increasing cases of addiction Antipsychotic Drugs resulting in drug abuse and addiction
      • 3.4.2. Schizophrenia patients are reported to be more prone to drug abuse and addiction.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antipsychotic Drugs, by Type, Application, Drug Class and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Antipsychotic Drugs (Value)
      • 5.2.1. Global Antipsychotic Drugs by: Type (Value)
        • 5.2.1.1. First Antipsychotic Drugs (Typical Antipsychotics)
        • 5.2.1.2. Second Antipsychotic Drugs (Newer Drugs)
        • 5.2.1.3. Third Antipsychotic Drugs
      • 5.2.2. Global Antipsychotic Drugs by: Application (Value)
        • 5.2.2.1. Schizophrenia
        • 5.2.2.2. Bipolar Disorder
        • 5.2.2.3. Depression
        • 5.2.2.4. Dementia
        • 5.2.2.5. Others
      • 5.2.3. Global Antipsychotic Drugs by: Drug Class (Value)
        • 5.2.3.1. Haldo
        • 5.2.3.2. Navane
        • 5.2.3.3. Invega
        • 5.2.3.4. Latuda
        • 5.2.3.5. Seroquel
        • 5.2.3.6. Risperdal
        • 5.2.3.7. Zyprexa
        • 5.2.3.8. Geodon
        • 5.2.3.9. Abilify
      • 5.2.4. Global Antipsychotic Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Antipsychotic Drugs (Volume)
      • 5.3.1. Global Antipsychotic Drugs by: Type (Volume)
        • 5.3.1.1. First Antipsychotic Drugs (Typical Antipsychotics)
        • 5.3.1.2. Second Antipsychotic Drugs (Newer Drugs)
        • 5.3.1.3. Third Antipsychotic Drugs
      • 5.3.2. Global Antipsychotic Drugs by: Application (Volume)
        • 5.3.2.1. Schizophrenia
        • 5.3.2.2. Bipolar Disorder
        • 5.3.2.3. Depression
        • 5.3.2.4. Dementia
        • 5.3.2.5. Others
      • 5.3.3. Global Antipsychotic Drugs by: Drug Class (Volume)
        • 5.3.3.1. Haldo
        • 5.3.3.2. Navane
        • 5.3.3.3. Invega
        • 5.3.3.4. Latuda
        • 5.3.3.5. Seroquel
        • 5.3.3.6. Risperdal
        • 5.3.3.7. Zyprexa
        • 5.3.3.8. Geodon
        • 5.3.3.9. Abilify
      • 5.3.4. Global Antipsychotic Drugs Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Antipsychotic Drugs (Price)
      • 5.4.1. Global Antipsychotic Drugs by: Type (Price)
  • 6. Antipsychotic Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Eli Lilly & Co. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Myers Squibb (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AstraZeneca (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Allergan (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Antipsychotic Drugs Sale, by Type, Application, Drug Class and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Antipsychotic Drugs (Value)
      • 7.2.1. Global Antipsychotic Drugs by: Type (Value)
        • 7.2.1.1. First Antipsychotic Drugs (Typical Antipsychotics)
        • 7.2.1.2. Second Antipsychotic Drugs (Newer Drugs)
        • 7.2.1.3. Third Antipsychotic Drugs
      • 7.2.2. Global Antipsychotic Drugs by: Application (Value)
        • 7.2.2.1. Schizophrenia
        • 7.2.2.2. Bipolar Disorder
        • 7.2.2.3. Depression
        • 7.2.2.4. Dementia
        • 7.2.2.5. Others
      • 7.2.3. Global Antipsychotic Drugs by: Drug Class (Value)
        • 7.2.3.1. Haldo
        • 7.2.3.2. Navane
        • 7.2.3.3. Invega
        • 7.2.3.4. Latuda
        • 7.2.3.5. Seroquel
        • 7.2.3.6. Risperdal
        • 7.2.3.7. Zyprexa
        • 7.2.3.8. Geodon
        • 7.2.3.9. Abilify
      • 7.2.4. Global Antipsychotic Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Antipsychotic Drugs (Volume)
      • 7.3.1. Global Antipsychotic Drugs by: Type (Volume)
        • 7.3.1.1. First Antipsychotic Drugs (Typical Antipsychotics)
        • 7.3.1.2. Second Antipsychotic Drugs (Newer Drugs)
        • 7.3.1.3. Third Antipsychotic Drugs
      • 7.3.2. Global Antipsychotic Drugs by: Application (Volume)
        • 7.3.2.1. Schizophrenia
        • 7.3.2.2. Bipolar Disorder
        • 7.3.2.3. Depression
        • 7.3.2.4. Dementia
        • 7.3.2.5. Others
      • 7.3.3. Global Antipsychotic Drugs by: Drug Class (Volume)
        • 7.3.3.1. Haldo
        • 7.3.3.2. Navane
        • 7.3.3.3. Invega
        • 7.3.3.4. Latuda
        • 7.3.3.5. Seroquel
        • 7.3.3.6. Risperdal
        • 7.3.3.7. Zyprexa
        • 7.3.3.8. Geodon
        • 7.3.3.9. Abilify
      • 7.3.4. Global Antipsychotic Drugs Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Antipsychotic Drugs (Price)
      • 7.4.1. Global Antipsychotic Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antipsychotic Drugs: by Type(USD Million)
  • Table 2. Antipsychotic Drugs First Antipsychotic Drugs (Typical Antipsychotics) , by Region USD Million (2015-2020)
  • Table 3. Antipsychotic Drugs Second Antipsychotic Drugs (Newer Drugs) , by Region USD Million (2015-2020)
  • Table 4. Antipsychotic Drugs Third Antipsychotic Drugs , by Region USD Million (2015-2020)
  • Table 5. Antipsychotic Drugs: by Application(USD Million)
  • Table 6. Antipsychotic Drugs Schizophrenia , by Region USD Million (2015-2020)
  • Table 7. Antipsychotic Drugs Bipolar Disorder , by Region USD Million (2015-2020)
  • Table 8. Antipsychotic Drugs Depression , by Region USD Million (2015-2020)
  • Table 9. Antipsychotic Drugs Dementia , by Region USD Million (2015-2020)
  • Table 10. Antipsychotic Drugs Others , by Region USD Million (2015-2020)
  • Table 11. Antipsychotic Drugs: by Drug Class(USD Million)
  • Table 12. Antipsychotic Drugs Haldo , by Region USD Million (2015-2020)
  • Table 13. Antipsychotic Drugs Navane , by Region USD Million (2015-2020)
  • Table 14. Antipsychotic Drugs Invega , by Region USD Million (2015-2020)
  • Table 15. Antipsychotic Drugs Latuda , by Region USD Million (2015-2020)
  • Table 16. Antipsychotic Drugs Seroquel , by Region USD Million (2015-2020)
  • Table 17. Antipsychotic Drugs Risperdal , by Region USD Million (2015-2020)
  • Table 18. Antipsychotic Drugs Zyprexa , by Region USD Million (2015-2020)
  • Table 19. Antipsychotic Drugs Geodon , by Region USD Million (2015-2020)
  • Table 20. Antipsychotic Drugs Abilify , by Region USD Million (2015-2020)
  • Table 21. South America Antipsychotic Drugs, by Country USD Million (2015-2020)
  • Table 22. South America Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 23. South America Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 24. South America Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 25. Brazil Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 26. Brazil Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 27. Brazil Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 28. Argentina Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 29. Argentina Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 30. Argentina Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 31. Rest of South America Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 32. Rest of South America Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 33. Rest of South America Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 34. Asia Pacific Antipsychotic Drugs, by Country USD Million (2015-2020)
  • Table 35. Asia Pacific Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 36. Asia Pacific Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 37. Asia Pacific Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 38. China Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 39. China Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 40. China Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 41. Japan Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 42. Japan Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 43. Japan Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 44. India Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 45. India Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 46. India Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 47. South Korea Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 48. South Korea Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 49. South Korea Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 50. Taiwan Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 51. Taiwan Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 52. Taiwan Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 53. Australia Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 54. Australia Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 55. Australia Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 56. Rest of Asia-Pacific Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 57. Rest of Asia-Pacific Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 58. Rest of Asia-Pacific Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 59. Europe Antipsychotic Drugs, by Country USD Million (2015-2020)
  • Table 60. Europe Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 61. Europe Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 62. Europe Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 63. Germany Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 64. Germany Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 65. Germany Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 66. France Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 67. France Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 68. France Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 69. Italy Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 70. Italy Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 71. Italy Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 72. United Kingdom Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 73. United Kingdom Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 74. United Kingdom Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 75. Netherlands Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 76. Netherlands Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 77. Netherlands Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 78. Rest of Europe Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 79. Rest of Europe Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 80. Rest of Europe Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 81. MEA Antipsychotic Drugs, by Country USD Million (2015-2020)
  • Table 82. MEA Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 83. MEA Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 84. MEA Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 85. Middle East Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 86. Middle East Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 87. Middle East Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 88. Africa Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 89. Africa Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 90. Africa Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 91. North America Antipsychotic Drugs, by Country USD Million (2015-2020)
  • Table 92. North America Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 93. North America Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 94. North America Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 95. United States Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 96. United States Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 97. United States Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 98. Canada Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 99. Canada Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 100. Canada Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 101. Mexico Antipsychotic Drugs, by Type USD Million (2015-2020)
  • Table 102. Mexico Antipsychotic Drugs, by Application USD Million (2015-2020)
  • Table 103. Mexico Antipsychotic Drugs, by Drug Class USD Million (2015-2020)
  • Table 104. Antipsychotic Drugs Sales: by Type(Tons)
  • Table 105. Antipsychotic Drugs Sales First Antipsychotic Drugs (Typical Antipsychotics) , by Region Tons (2015-2020)
  • Table 106. Antipsychotic Drugs Sales Second Antipsychotic Drugs (Newer Drugs) , by Region Tons (2015-2020)
  • Table 107. Antipsychotic Drugs Sales Third Antipsychotic Drugs , by Region Tons (2015-2020)
  • Table 108. Antipsychotic Drugs Sales: by Application(Tons)
  • Table 109. Antipsychotic Drugs Sales Schizophrenia , by Region Tons (2015-2020)
  • Table 110. Antipsychotic Drugs Sales Bipolar Disorder , by Region Tons (2015-2020)
  • Table 111. Antipsychotic Drugs Sales Depression , by Region Tons (2015-2020)
  • Table 112. Antipsychotic Drugs Sales Dementia , by Region Tons (2015-2020)
  • Table 113. Antipsychotic Drugs Sales Others , by Region Tons (2015-2020)
  • Table 114. Antipsychotic Drugs Sales: by Drug Class(Tons)
  • Table 115. Antipsychotic Drugs Sales Haldo , by Region Tons (2015-2020)
  • Table 116. Antipsychotic Drugs Sales Navane , by Region Tons (2015-2020)
  • Table 117. Antipsychotic Drugs Sales Invega , by Region Tons (2015-2020)
  • Table 118. Antipsychotic Drugs Sales Latuda , by Region Tons (2015-2020)
  • Table 119. Antipsychotic Drugs Sales Seroquel , by Region Tons (2015-2020)
  • Table 120. Antipsychotic Drugs Sales Risperdal , by Region Tons (2015-2020)
  • Table 121. Antipsychotic Drugs Sales Zyprexa , by Region Tons (2015-2020)
  • Table 122. Antipsychotic Drugs Sales Geodon , by Region Tons (2015-2020)
  • Table 123. Antipsychotic Drugs Sales Abilify , by Region Tons (2015-2020)
  • Table 124. South America Antipsychotic Drugs Sales, by Country Tons (2015-2020)
  • Table 125. South America Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 126. South America Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 127. South America Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 128. Brazil Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 129. Brazil Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 130. Brazil Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 131. Argentina Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 132. Argentina Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 133. Argentina Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 134. Rest of South America Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 135. Rest of South America Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 136. Rest of South America Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 137. Asia Pacific Antipsychotic Drugs Sales, by Country Tons (2015-2020)
  • Table 138. Asia Pacific Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 139. Asia Pacific Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 140. Asia Pacific Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 141. China Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 142. China Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 143. China Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 144. Japan Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 145. Japan Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 146. Japan Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 147. India Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 148. India Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 149. India Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 150. South Korea Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 151. South Korea Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 152. South Korea Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 153. Taiwan Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 154. Taiwan Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 155. Taiwan Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 156. Australia Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 157. Australia Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 158. Australia Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 159. Rest of Asia-Pacific Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 160. Rest of Asia-Pacific Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 161. Rest of Asia-Pacific Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 162. Europe Antipsychotic Drugs Sales, by Country Tons (2015-2020)
  • Table 163. Europe Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 164. Europe Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 165. Europe Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 166. Germany Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 167. Germany Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 168. Germany Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 169. France Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 170. France Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 171. France Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 172. Italy Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 173. Italy Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 174. Italy Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 175. United Kingdom Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 176. United Kingdom Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 177. United Kingdom Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 178. Netherlands Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 179. Netherlands Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 180. Netherlands Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 181. Rest of Europe Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 182. Rest of Europe Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 183. Rest of Europe Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 184. MEA Antipsychotic Drugs Sales, by Country Tons (2015-2020)
  • Table 185. MEA Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 186. MEA Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 187. MEA Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 188. Middle East Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 189. Middle East Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 190. Middle East Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 191. Africa Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 192. Africa Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 193. Africa Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 194. North America Antipsychotic Drugs Sales, by Country Tons (2015-2020)
  • Table 195. North America Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 196. North America Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 197. North America Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 198. United States Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 199. United States Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 200. United States Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 201. Canada Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 202. Canada Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 203. Canada Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 204. Mexico Antipsychotic Drugs Sales, by Type Tons (2015-2020)
  • Table 205. Mexico Antipsychotic Drugs Sales, by Application Tons (2015-2020)
  • Table 206. Mexico Antipsychotic Drugs Sales, by Drug Class Tons (2015-2020)
  • Table 207. Antipsychotic Drugs: by Type(USD/Units)
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Company Basic Information, Sales Area and Its Competitors
  • Table 211. Company Basic Information, Sales Area and Its Competitors
  • Table 212. Company Basic Information, Sales Area and Its Competitors
  • Table 213. Company Basic Information, Sales Area and Its Competitors
  • Table 214. Company Basic Information, Sales Area and Its Competitors
  • Table 215. Antipsychotic Drugs: by Type(USD Million)
  • Table 216. Antipsychotic Drugs First Antipsychotic Drugs (Typical Antipsychotics) , by Region USD Million (2021-2026)
  • Table 217. Antipsychotic Drugs Second Antipsychotic Drugs (Newer Drugs) , by Region USD Million (2021-2026)
  • Table 218. Antipsychotic Drugs Third Antipsychotic Drugs , by Region USD Million (2021-2026)
  • Table 219. Antipsychotic Drugs: by Application(USD Million)
  • Table 220. Antipsychotic Drugs Schizophrenia , by Region USD Million (2021-2026)
  • Table 221. Antipsychotic Drugs Bipolar Disorder , by Region USD Million (2021-2026)
  • Table 222. Antipsychotic Drugs Depression , by Region USD Million (2021-2026)
  • Table 223. Antipsychotic Drugs Dementia , by Region USD Million (2021-2026)
  • Table 224. Antipsychotic Drugs Others , by Region USD Million (2021-2026)
  • Table 225. Antipsychotic Drugs: by Drug Class(USD Million)
  • Table 226. Antipsychotic Drugs Haldo , by Region USD Million (2021-2026)
  • Table 227. Antipsychotic Drugs Navane , by Region USD Million (2021-2026)
  • Table 228. Antipsychotic Drugs Invega , by Region USD Million (2021-2026)
  • Table 229. Antipsychotic Drugs Latuda , by Region USD Million (2021-2026)
  • Table 230. Antipsychotic Drugs Seroquel , by Region USD Million (2021-2026)
  • Table 231. Antipsychotic Drugs Risperdal , by Region USD Million (2021-2026)
  • Table 232. Antipsychotic Drugs Zyprexa , by Region USD Million (2021-2026)
  • Table 233. Antipsychotic Drugs Geodon , by Region USD Million (2021-2026)
  • Table 234. Antipsychotic Drugs Abilify , by Region USD Million (2021-2026)
  • Table 235. South America Antipsychotic Drugs, by Country USD Million (2021-2026)
  • Table 236. South America Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 237. South America Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 238. South America Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 239. Brazil Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 240. Brazil Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 241. Brazil Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 242. Argentina Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 243. Argentina Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 244. Argentina Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 245. Rest of South America Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 246. Rest of South America Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 247. Rest of South America Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 248. Asia Pacific Antipsychotic Drugs, by Country USD Million (2021-2026)
  • Table 249. Asia Pacific Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 250. Asia Pacific Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 251. Asia Pacific Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 252. China Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 253. China Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 254. China Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 255. Japan Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 256. Japan Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 257. Japan Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 258. India Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 259. India Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 260. India Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 261. South Korea Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 262. South Korea Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 263. South Korea Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 264. Taiwan Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 265. Taiwan Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 266. Taiwan Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 267. Australia Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 268. Australia Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 269. Australia Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 270. Rest of Asia-Pacific Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 271. Rest of Asia-Pacific Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 272. Rest of Asia-Pacific Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 273. Europe Antipsychotic Drugs, by Country USD Million (2021-2026)
  • Table 274. Europe Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 275. Europe Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 276. Europe Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 277. Germany Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 278. Germany Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 279. Germany Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 280. France Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 281. France Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 282. France Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 283. Italy Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 284. Italy Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 285. Italy Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 286. United Kingdom Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 287. United Kingdom Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 288. United Kingdom Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 289. Netherlands Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 290. Netherlands Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 291. Netherlands Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 292. Rest of Europe Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 293. Rest of Europe Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 294. Rest of Europe Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 295. MEA Antipsychotic Drugs, by Country USD Million (2021-2026)
  • Table 296. MEA Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 297. MEA Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 298. MEA Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 299. Middle East Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 300. Middle East Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 301. Middle East Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 302. Africa Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 303. Africa Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 304. Africa Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 305. North America Antipsychotic Drugs, by Country USD Million (2021-2026)
  • Table 306. North America Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 307. North America Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 308. North America Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 309. United States Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 310. United States Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 311. United States Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 312. Canada Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 313. Canada Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 314. Canada Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 315. Mexico Antipsychotic Drugs, by Type USD Million (2021-2026)
  • Table 316. Mexico Antipsychotic Drugs, by Application USD Million (2021-2026)
  • Table 317. Mexico Antipsychotic Drugs, by Drug Class USD Million (2021-2026)
  • Table 318. Antipsychotic Drugs Sales: by Type(Tons)
  • Table 319. Antipsychotic Drugs Sales First Antipsychotic Drugs (Typical Antipsychotics) , by Region Tons (2021-2026)
  • Table 320. Antipsychotic Drugs Sales Second Antipsychotic Drugs (Newer Drugs) , by Region Tons (2021-2026)
  • Table 321. Antipsychotic Drugs Sales Third Antipsychotic Drugs , by Region Tons (2021-2026)
  • Table 322. Antipsychotic Drugs Sales: by Application(Tons)
  • Table 323. Antipsychotic Drugs Sales Schizophrenia , by Region Tons (2021-2026)
  • Table 324. Antipsychotic Drugs Sales Bipolar Disorder , by Region Tons (2021-2026)
  • Table 325. Antipsychotic Drugs Sales Depression , by Region Tons (2021-2026)
  • Table 326. Antipsychotic Drugs Sales Dementia , by Region Tons (2021-2026)
  • Table 327. Antipsychotic Drugs Sales Others , by Region Tons (2021-2026)
  • Table 328. Antipsychotic Drugs Sales: by Drug Class(Tons)
  • Table 329. Antipsychotic Drugs Sales Haldo , by Region Tons (2021-2026)
  • Table 330. Antipsychotic Drugs Sales Navane , by Region Tons (2021-2026)
  • Table 331. Antipsychotic Drugs Sales Invega , by Region Tons (2021-2026)
  • Table 332. Antipsychotic Drugs Sales Latuda , by Region Tons (2021-2026)
  • Table 333. Antipsychotic Drugs Sales Seroquel , by Region Tons (2021-2026)
  • Table 334. Antipsychotic Drugs Sales Risperdal , by Region Tons (2021-2026)
  • Table 335. Antipsychotic Drugs Sales Zyprexa , by Region Tons (2021-2026)
  • Table 336. Antipsychotic Drugs Sales Geodon , by Region Tons (2021-2026)
  • Table 337. Antipsychotic Drugs Sales Abilify , by Region Tons (2021-2026)
  • Table 338. South America Antipsychotic Drugs Sales, by Country Tons (2021-2026)
  • Table 339. South America Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 340. South America Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 341. South America Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 342. Brazil Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 343. Brazil Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 344. Brazil Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 345. Argentina Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 346. Argentina Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 347. Argentina Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 348. Rest of South America Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 349. Rest of South America Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 350. Rest of South America Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 351. Asia Pacific Antipsychotic Drugs Sales, by Country Tons (2021-2026)
  • Table 352. Asia Pacific Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 353. Asia Pacific Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 354. Asia Pacific Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 355. China Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 356. China Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 357. China Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 358. Japan Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 359. Japan Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 360. Japan Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 361. India Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 362. India Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 363. India Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 364. South Korea Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 365. South Korea Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 366. South Korea Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 367. Taiwan Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 368. Taiwan Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 369. Taiwan Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 370. Australia Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 371. Australia Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 372. Australia Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 373. Rest of Asia-Pacific Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 374. Rest of Asia-Pacific Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 375. Rest of Asia-Pacific Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 376. Europe Antipsychotic Drugs Sales, by Country Tons (2021-2026)
  • Table 377. Europe Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 378. Europe Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 379. Europe Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 380. Germany Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 381. Germany Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 382. Germany Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 383. France Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 384. France Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 385. France Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 386. Italy Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 387. Italy Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 388. Italy Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 389. United Kingdom Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 390. United Kingdom Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 391. United Kingdom Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 392. Netherlands Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 393. Netherlands Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 394. Netherlands Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 395. Rest of Europe Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 396. Rest of Europe Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 397. Rest of Europe Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 398. MEA Antipsychotic Drugs Sales, by Country Tons (2021-2026)
  • Table 399. MEA Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 400. MEA Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 401. MEA Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 402. Middle East Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 403. Middle East Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 404. Middle East Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 405. Africa Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 406. Africa Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 407. Africa Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 408. North America Antipsychotic Drugs Sales, by Country Tons (2021-2026)
  • Table 409. North America Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 410. North America Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 411. North America Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 412. United States Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 413. United States Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 414. United States Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 415. Canada Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 416. Canada Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 417. Canada Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 418. Mexico Antipsychotic Drugs Sales, by Type Tons (2021-2026)
  • Table 419. Mexico Antipsychotic Drugs Sales, by Application Tons (2021-2026)
  • Table 420. Mexico Antipsychotic Drugs Sales, by Drug Class Tons (2021-2026)
  • Table 421. Antipsychotic Drugs: by Type(USD/Units)
  • Table 422. Research Programs/Design for This Report
  • Table 423. Key Data Information from Secondary Sources
  • Table 424. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antipsychotic Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Antipsychotic Drugs: by Application USD Million (2015-2020)
  • Figure 6. Global Antipsychotic Drugs: by Drug Class USD Million (2015-2020)
  • Figure 7. South America Antipsychotic Drugs Share (%), by Country
  • Figure 8. Asia Pacific Antipsychotic Drugs Share (%), by Country
  • Figure 9. Europe Antipsychotic Drugs Share (%), by Country
  • Figure 10. MEA Antipsychotic Drugs Share (%), by Country
  • Figure 11. North America Antipsychotic Drugs Share (%), by Country
  • Figure 12. Global Antipsychotic Drugs: by Type Tons (2015-2020)
  • Figure 13. Global Antipsychotic Drugs: by Application Tons (2015-2020)
  • Figure 14. Global Antipsychotic Drugs: by Drug Class Tons (2015-2020)
  • Figure 15. South America Antipsychotic Drugs Share (%), by Country
  • Figure 16. Asia Pacific Antipsychotic Drugs Share (%), by Country
  • Figure 17. Europe Antipsychotic Drugs Share (%), by Country
  • Figure 18. MEA Antipsychotic Drugs Share (%), by Country
  • Figure 19. North America Antipsychotic Drugs Share (%), by Country
  • Figure 20. Global Antipsychotic Drugs: by Type USD/Units (2015-2020)
  • Figure 21. Global Antipsychotic Drugs share by Players 2020 (%)
  • Figure 22. Global Antipsychotic Drugs share by Players (Top 3) 2020(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Eli Lilly & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Eli Lilly & Co. (United States) Revenue: by Geography 2020
  • Figure 26. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 27. Bristol-Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 28. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 30. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 32. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2020
  • Figure 34. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 35. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 36. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 37. Allergan (Ireland) Revenue: by Geography 2020
  • Figure 38. Global Antipsychotic Drugs: by Type USD Million (2021-2026)
  • Figure 39. Global Antipsychotic Drugs: by Application USD Million (2021-2026)
  • Figure 40. Global Antipsychotic Drugs: by Drug Class USD Million (2021-2026)
  • Figure 41. South America Antipsychotic Drugs Share (%), by Country
  • Figure 42. Asia Pacific Antipsychotic Drugs Share (%), by Country
  • Figure 43. Europe Antipsychotic Drugs Share (%), by Country
  • Figure 44. MEA Antipsychotic Drugs Share (%), by Country
  • Figure 45. North America Antipsychotic Drugs Share (%), by Country
  • Figure 46. Global Antipsychotic Drugs: by Type Tons (2021-2026)
  • Figure 47. Global Antipsychotic Drugs: by Application Tons (2021-2026)
  • Figure 48. Global Antipsychotic Drugs: by Drug Class Tons (2021-2026)
  • Figure 49. South America Antipsychotic Drugs Share (%), by Country
  • Figure 50. Asia Pacific Antipsychotic Drugs Share (%), by Country
  • Figure 51. Europe Antipsychotic Drugs Share (%), by Country
  • Figure 52. MEA Antipsychotic Drugs Share (%), by Country
  • Figure 53. North America Antipsychotic Drugs Share (%), by Country
  • Figure 54. Global Antipsychotic Drugs: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Eli Lilly & Co. (United States)
  • Bristol-Myers Squibb (United States)
  • AstraZeneca (United Kingdom)
  • Pfizer Inc. (United States)
  • GlaxoSmithKline plc. (United Kingdom)
  • Johnson & Johnson (United States)
  • Allergan (Ireland)
Additional players considered in the study are as follows:
Takeda Pharmaceutical Company Limited (Japan) , H. Lundbeck A/S (Denmark) , Otsuka Pharmaceuticals (Japan) , Proteus Digital Health (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation